Caplin Point Laboratories (524742) investor relations material

Executive summary

• Achieved strong and consistent growth in Q3 and 9M FY26, with revenue and profitability outpacing peers and recognized as a top wealth creator in India.

• Strategic focus on regulated and emerging markets, especially the US and Latin America, with consistent product approvals, launches, and expansion in Mexico and Chile.

• Major operational initiatives include rollout of video SOPs, automation, and recruitment of senior regulatory experts.

• Investments in capacity, technology, and people, with vertical integration and product portfolio diversification.

• Free cash reserves and liquid assets remain strong, supporting ongoing and future investments.

Financial highlights

• Q3 FY26 revenue from operations rose 10.1% YoY to Rs 543 Cr; 9M FY26 revenue up 11.2% YoY to Rs 1,674 Cr.

• Q3 FY26 EBITDA increased 15.3% YoY to Rs 223 Cr; 9M FY26 EBITDA up 17.1% YoY to Rs 644 Cr, with margin at 38.5%.

• Q3 FY26 PAT grew 18.4% YoY to Rs 177 Cr; 9M FY26 PAT up 20.5% YoY to Rs 477 Cr, with PAT margin at 28.5%.

• Gross margin for 9M FY26 was 60.9%; basic EPS for 9M FY26 increased 19.6% to Rs 61.98.

• Free cash flow for 9M FY26 at Rs 188 Cr after capex; receivables at 121 days.

Outlook and guidance

• High double-digit revenue growth expected in US-focused entities and new product launches in regulated markets over the next 12-15 months.

• Oncology API facility and new manufacturing capacities to be operational by FY27.

• Next 18-24 months seen as a consolidation phase, with significant growth anticipated from 2028 onward.

• Margins expected to remain stable in the 26%-29% range.

• Capex budget of Rs 1,000+ Cr, with 50% nearing completion, fully funded by internal accruals.